Last Updated : July 24, 2024
Details
Generic Name:
trastuzumab deruxtecan
Project Status:
Not filed
Therapeutic Area:
Metastatic HER2-positive breast cancer
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Enhertu
Project Line:
Reimbursement Review
Project Number:
NS0035-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
As monotherapy, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab emtansine (T-DM1)
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024